Zobrazeno 1 - 10
of 243
pro vyhledávání: '"Peter Ferenci"'
Publikováno v:
Expert Opinion on Investigational Drugs. 27:561-567
INTRODUCTION Wilson disease (WD) is a genetic disorder in which excess toxic copper accumulates in the liver, brain, and other tissues leading to severe and life-threatening symptoms. Copper overload can be assessed as non-ceruloplasmin-bound copper
Autor:
Wolfgang Korak, Peter Ferenci, S Moser, Hermann Laferl, B Bauer, Martin Bischof, Andreas Maieron, M Schleicher, Barbara Bognar, Michael Gschwantler, Rudolf E. Stauber, Wolfgang Vogel, Harald Hofer
Publikováno v:
Wiener klinische Wochenschrift. 130:54-61
Patients with a history of intravenous drug abuse included in an official opioid substitution program represent an important subgroup of patients with chronic hepatitis C. The objective of this study was to assess the efficacy of and adherence to tre
Autor:
Harald Hofer, Martin Gajdošík, Emina Halilbasic, Christian Rechling, Judith Stift, Michael Trauner, Petra Steindl-Munda, Christian Kienbacher, Ladislav Valkovič, Stefan Traussnigg, Martin Krššák, Siegfried Trattnig, Fritz Wrba, Peter Ferenci
Publikováno v:
Liver International
Background and Aims With the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) non-invasive tools obtaining pathomechanistic insights to improve risk stratification are urgently needed. We therefore explored hi
Autor:
Sandra Beinhardt, E Gutic, Karin Kozbial, Thomas Reiberger, Michael Gschwantler, Peter Ferenci, Hermann Laferl, S Moser
Publikováno v:
Zeitschrift für Gastroenterologie. 55:e28-e56
Autor:
Michael Gschwantler, M Srasser, Rudolf E. Stauber, Remy Schwarzer, Heinz Zoller, AF Stättermayer, Sandra Beinhardt, Andreas Maieron, Karin Kozbial, R Al-Zoairy, Peter Ferenci, S Moser, Harald Hofer, Christian Datz, Petra Steindl-Munda, Hermann Laferl
Publikováno v:
Zeitschrift für Gastroenterologie. 55:e28-e56
Autor:
Markus Peck-Radosavljevic, Arnulf Ferlitsch, Michael Trauner, Rafael Paternostro, A. Etschmaier, S Hametner, P. Salzl, Peter Quehenberger, Monika Ferlitsch, Thomas Reiberger, Peter Ferenci, Thomas Horvatits, Andreas Maieron, Harald Hofer, Karoline Rutter
Publikováno v:
Digestive and Liver Disease. 48:1194-1199
Treatment of chronic hepatitis C virus (HCV) infection was revolutionized within the last years. Interferon free antiviral regimens are not accessible without limitations. Combination of peginterferon/ribavirin with first generation direct acting ant
Autor:
Peter Ferenci, Tami Pilot-Matias, N. Mobashery, Jordan J. Feld, George V. Papatheodoridis, Christophe Hézode, Christophe Moreno, Tarek Hassanein, Stefan Zeuzem, Yao Yu, Roula B. Qaqish, Rebecca Redman, Tarik Asselah, Magdy Elkhashab
Publikováno v:
The Lancet Gastroenterology & Hepatology. 1:25-35
Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial d
Autor:
Gregory T. Everson, Julian Zhou, Peter Ferenci, Ellen S. Yetzer, Eric M. Yoshida, Savino Bruno, Pietro Andreone, Curtis Cooper, Nancy S. Shulman, Sophie Le Pogam, Teresita Beltran-Jaramillo, Mercidita T. Navarro, Mitchell L. Shiffman, Athina Voulgari, Isabel Najera, Christophe Hézode, Michael J. Brunda, Stefan Zeuzem
Publikováno v:
Liver International. 35:108-119
Background & Aims Danoprevir is a hepatitis C virus (HCV) protease inhibitor with activity against genotypes (G)1/G4, which is maintained at lower doses by ritonavir-boosting. We report results of a large, randomized, active-controlled phase IIb stud
Autor:
Roger Trinh, Marina Berenguer, Marcos Pedrosa, Heiner Wedemeyer, Juan Carlos Lopez-Talavera, Gregory T. Everson, Sandra S. Lovell, Peter Ferenci, Michael W. Fried, Xavier Forns, Fred Poordad, Mitchell L. Shiffman
Publikováno v:
Liver International
Background & Aims Thrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic synthetic dysfunction respectively. Patients infected with hepatitis C virus (HCV) with these surrogates have reduced likelihood of sus
Autor:
Mariem Charafeddine, Henning Kleine, Peter Ferenci, David Back, Suzanne Norris, Dominique Larrey, Eric Crown, Robert Flisiak, Manuela Curescu, Patrick K. Dorr, Suzanne Bourgeois, Mark Bondin, Peter Buggisch, Fiona Marra
Publikováno v:
Journal of Viral Hepatitis
JOURNAL OF VIRAL HEPATITIS
Journal of Viral Hepatitis, Wiley-Blackwell, 2019, 26 (6), pp.685-696. ⟨10.1111/jvh.13080⟩
JOURNAL OF VIRAL HEPATITIS
Journal of Viral Hepatitis, Wiley-Blackwell, 2019, 26 (6), pp.685-696. ⟨10.1111/jvh.13080⟩
International audience; Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4. To evaluate